MorphoSys AG (ETR:MOR) received a €59.00 ($69.41) target price from research analysts at HSBC Holdings plc in a note issued to investors on Friday, July 14th. The firm currently has a “neutral” rating on the stock.
Other equities analysts also recently issued reports about the company. Commerzbank Ag set a €76.00 ($89.41) target price on MorphoSys AG and gave the company a “buy” rating in a research note on Tuesday, May 30th. Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) target price on MorphoSys AG and gave the stock a “neutral” rating in a report on Tuesday, June 6th. Berenberg Bank set a €68.00 ($80.00) target price on MorphoSys AG and gave the stock a “buy” rating in a report on Friday, July 14th. Finally, Independent Research GmbH set a €77.00 ($90.59) price target on MorphoSys AG and gave the company a “buy” rating in a report on Monday, May 29th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of €69.57 ($81.85).
MorphoSys AG (MOR) opened at 56.121 on Friday. MorphoSys AG has a 52 week low of €35.72 and a 52 week high of €70.90. The company’s market capitalization is €1.63 billion. The company’s 50 day moving average price is €62.01 and its 200-day moving average price is €57.64.
MorphoSys AG Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
What are top analysts saying about MorphoSys AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MorphoSys AG and related companies.